UA93181C2 - СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ - Google Patents

СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ

Info

Publication number
UA93181C2
UA93181C2 UAA200609258A UAA200609258A UA93181C2 UA 93181 C2 UA93181 C2 UA 93181C2 UA A200609258 A UAA200609258 A UA A200609258A UA A200609258 A UAA200609258 A UA A200609258A UA 93181 C2 UA93181 C2 UA 93181C2
Authority
UA
Ukraine
Prior art keywords
antibody
preparing
cells
peptide
endogenously
Prior art date
Application number
UAA200609258A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Рональд Брендли Дематтос
Ума Кучиботла
Хсю-Чунг Янг
Дон Б. Макклюр
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of UA93181C2 publication Critical patent/UA93181C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
UAA200609258A 2004-02-23 2005-02-17 СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ UA93181C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23

Publications (1)

Publication Number Publication Date
UA93181C2 true UA93181C2 (ru) 2011-01-25

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200609258A UA93181C2 (ru) 2004-02-23 2005-02-17 СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ

Country Status (20)

Country Link
US (1) US20070190046A1 (cg-RX-API-DMAC7.html)
EP (1) EP1720909B1 (cg-RX-API-DMAC7.html)
JP (1) JP4851348B2 (cg-RX-API-DMAC7.html)
KR (2) KR100889430B1 (cg-RX-API-DMAC7.html)
CN (1) CN1922209B (cg-RX-API-DMAC7.html)
AT (1) ATE534667T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005217596B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507856A (cg-RX-API-DMAC7.html)
CA (1) CA2556436C (cg-RX-API-DMAC7.html)
CY (1) CY1112162T1 (cg-RX-API-DMAC7.html)
DK (1) DK1720909T3 (cg-RX-API-DMAC7.html)
EA (1) EA009872B1 (cg-RX-API-DMAC7.html)
ES (1) ES2375627T3 (cg-RX-API-DMAC7.html)
IL (1) IL177611A (cg-RX-API-DMAC7.html)
NO (1) NO20064239L (cg-RX-API-DMAC7.html)
PL (1) PL1720909T3 (cg-RX-API-DMAC7.html)
PT (1) PT1720909E (cg-RX-API-DMAC7.html)
SI (1) SI1720909T1 (cg-RX-API-DMAC7.html)
UA (1) UA93181C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005082939A2 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
MX358175B (es) 2005-12-12 2018-08-08 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
US7892544B2 (en) 2006-07-14 2011-02-22 Ac Immune Sa Humanized anti-beta-amyloid antibody
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
HUE034512T2 (en) 2007-01-05 2018-02-28 Univ Zuerich A method for providing disease-specific binding molecules and targets
WO2008084402A2 (en) 2007-01-11 2008-07-17 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
RU2542967C2 (ru) * 2007-10-05 2015-02-27 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
EA201190025A1 (ru) 2008-11-25 2012-12-28 Байоджен Айдек Ма Инк. ПРИМЕНЕНИЕ АНТАГОНИСТОВ DR6 И p75 ДЛЯ ПРОМОТИРОВАНИЯ ВЫЖИВАНИЯ КЛЕТОК НЕРВНОЙ СИСТЕМЫ
BRPI0923157B1 (pt) 2008-12-19 2021-12-28 University Of Zürich Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática
WO2011060246A2 (en) 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
CN102933601B (zh) 2010-04-15 2016-06-08 Abbvie公司 β淀粉样蛋白结合蛋白
MY164579A (en) 2010-07-30 2018-01-15 Ac Immune Sa Safe and functional humanized antibodies
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
WO2014039781A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye & Ear Infirmary Treating hearing loss
JP6751344B2 (ja) 2013-09-13 2020-09-02 ジェネンテック， インコーポレイテッド 精製された組み換えポリペプチドを含む方法及び組成物
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
KR102362222B1 (ko) 2016-05-16 2022-02-11 더 제너럴 하스피탈 코포레이션 폐 상피 공학에서 인간 기도 줄기 세포
WO2018031334A1 (en) * 2016-08-11 2018-02-15 Eli Lilly And Company Aminothiazines and their use as bace1 inhibitors
AU2018321335B2 (en) 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP2025506411A (ja) 2022-02-03 2025-03-11 イーライ リリー アンド カンパニー アルツハイマー病の診断及び治療のための局所タウイメージング

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT951466E (pt) 1996-12-23 2009-04-09 Lilly Co Eli Compostos cicloalquilo, lactama, lactona e relacionados, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da libertação do péptido β-amilóide e/ou da sua síntese pela utilização de tais compostos
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
MXPA02008145A (es) * 2000-02-24 2004-04-05 Univ Washington Anticuerpos humanizados que secuestran al peptido beta amiloide.
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide

Also Published As

Publication number Publication date
AU2005217596B2 (en) 2012-01-19
US20070190046A1 (en) 2007-08-16
CN1922209B (zh) 2012-09-05
KR20090005410A (ko) 2009-01-13
JP2008500279A (ja) 2008-01-10
SI1720909T1 (sl) 2012-01-31
ATE534667T1 (de) 2011-12-15
IL177611A (en) 2013-05-30
DK1720909T3 (da) 2012-01-30
CY1112162T1 (el) 2015-12-09
PL1720909T3 (pl) 2012-04-30
CA2556436C (en) 2014-04-01
EA009872B1 (ru) 2008-04-28
NO20064239L (no) 2006-11-20
EA200601545A1 (ru) 2007-02-27
PT1720909E (pt) 2011-12-23
BRPI0507856A (pt) 2007-07-10
JP4851348B2 (ja) 2012-01-11
KR100889430B1 (ko) 2009-03-23
ES2375627T3 (es) 2012-03-02
IL177611A0 (en) 2006-12-10
AU2005217596A1 (en) 2005-09-09
KR20060126785A (ko) 2006-12-08
CN1922209A (zh) 2007-02-28
EP1720909A2 (en) 2006-11-15
EP1720909B1 (en) 2011-11-23
CA2556436A1 (en) 2005-09-09
WO2005082939A3 (en) 2005-10-27
WO2005082939A2 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
UA93181C2 (ru) СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ
SG149061A1 (en) Definitive endoderm
MX2018012512A (es) Poblaciones de celula madre de la placenta.
MX2009010361A (es) Anticuerpos il-12 anti-humanos cristalinos.
MX2009002991A (es) Indicador de esterilizacion.
NZ592897A (en) Crystals of laquinimod sodium, and process for the manufacture thereof
TW200631917A (en) Synthetic aggregates comprising sewage sludge and other waste materials and methods for producing such aggregates
SG138449A1 (en) Enumeration method for the link clock rate and the pixel/audio clock rate
MX2009004351A (es) Anticuerpos anti-htnfalfa cristalinos.
WO2007134294A3 (en) Novel chlorella species and uses therefor
NZ592159A (en) Means and methods for influencing the stability of antibody producing cells
TW200700092A (en) Tigecycline compositions and methods of preparation
WO2008009639A3 (en) New indications for direct thrombin inhibitors
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
UA93531C2 (en) Novel hydrogen sulfate salt
DE502005004058D1 (de) Verfahren zur deacylierung von lipopeptiden
CY1112973T1 (el) Περαιτερω κρυσταλλικες μορφες ροσταφουροξινης
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
PH12021550950A1 (en) Method for culturing cord blood-derived natural killer cells using transformed t cells
BRPI0509302A (pt) método de purificação de oócitos de uma composição que compreende material fecal
EP1895026A4 (en) METHOD FOR PULLING A SILICON CRYSTAL AND THEN RENEWED SILICON INGREDIENT
SG148168A1 (en) Genetically modified microorganism and process for production of macrolide compound using the microorganism
TN2009000147A1 (en) Crystal modifications -3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-d ione
DK1651754T3 (da) Myelomcellekultur i transferrinfrit medium med lavt jernindhold